FORM PTO-1390 (REV 11-98) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371

ATTORNEY'S DOCKET NUMBER: 146.1365

U.S. APPLICATION NO. (If known, see 37 CFR 1.5): 09/831804

INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/FR99/02739	November 9, 1999	November 10, 1998

TITLE OF INVENTION: CANDIDA ALBICANS tfIIIA GENE (CatfIIIA) AND THE CODED CATFIIIA PROTEIN

APPLICANT(S) FOR DO/EO/US: F. BORDON-PALLIER et al

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. [x] This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. [ ] This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. [x] This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. [ ] A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. [x] A copy of the International Application as filed (35 U.S.C. 371(c)(2))
   a. [x] is transmitted herewith (required only if not transmitted by the International Bureau).
   b. [ ] has been transmitted by the International Bureau.
   c. [ ] is not required, as the application was filed in the United States Receiving Office (RO/US).
6. [x] A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. [ ] Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
   a. [ ] are transmitted herewith (required only if not transmitted by the International Bureau).
   b. [ ] have been transmitted by the International Bureau.
   c. [ ] have not been made; however, the time limit for making such amendments has NOT expired.
   d. [ ] have not been made and will not be made.
8. [ ] A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. [x] An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). Unexecuted
10. [ ] A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern document(s) or information included:

11. [x] An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. [ ] An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. [x] A FIRST preliminary amendment.
    [ ] A SECOND or SUBSEQUENT preliminary amendment.
14. [ ] A substitute specification.
15. [ ] A change of power of attorney and/or address letter.
16. [x] Other items or information: PCT/IB/306; International Preliminary Examination Report in English

U.S. APPLICATION NO (if known, see 37 CFR 1.5)	INTERNATIONAL APPLICATION NO	ATTORNEY'S DOCKET NUMBER
09/831804	PCT/FR99/02739	146.1365

17. [xx] The following fees are submitted:

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):	CALCULATIONS PTO USE ONLY
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO $970.00	$1000.00
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO $840.00	
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO $760.00	
International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) $670.00	
International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) $96.00	
ENTER APPROPRIATE BASIC FEE AMOUNT =	$ 1000.00
Surcharge of $130.00 for furnishing the oath or declaration later than [ ] 20 [ ] 30 months from the earliest claimed priority date (37 CFR 1.492(e)).	$

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	
Total claims	25 - 20 =	5	X $18.00	$ 90.00
Independent claims	- 3 =		X $78.00	$
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ $260.00	$
TOTAL OF ABOVE CALCULATIONS =				$1090.00
Reduction of 1/2 for filing by small entity, if applicable. A Small Entity Statement must also by filed (Note 37 CFR 1.9, 1.27, 1.28).				$
SUBTOTAL =				$1090.00
Processing fee of $130.00 for furnishing the English translation later than [ ] 20 [ ] 30 months from the earliest claimed priority date (37 CFR 1.492(f)).			+	$
TOTAL NATIONAL FEE =				$1090.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). $40.00 per property			+	$
TOTAL FEES ENCLOSED =				$1090.00
Amount to be: refunded				$
charged				$

a. [X] PTO FORM 2038 is enclosed ~~A check in the amount of $ _____ to cover the above fees is enclosed.~~

b. [ ] Please charge my Deposit Account No. _____ in the amount of $_____ to cover the above fees. A duplicate copy of this sheet is enclosed.

c. [x] The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 02-2275 . A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Bierman, Muserlian and Lucas
600 Third Avenue
New York, NY 10016

SIGNATURE

Charles A. Muserlian
NAME

19,683
REGISTRATION NUMBER

146.1365

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: : PCT Date: 11/9/99
F. BORDON-PALLIER et al :
PCT No.: PCT/FR99/02739 :
Filed: Concurrently Herewith :
For: CANDIDA...CATFIIIA PROTEIN :

600 Third Avenue
New York N.Y. 10016

PRELIMINARY AMENDMENT

Asst. Commissioner for Patents
Washington, D.C. 20231

Sir:

Please amend this application as follows:

IN THE SPECIFICATION:

Page 1, before line 1, insert

--This application is a 371 of PCT/FR99/02739 filed November 9, 1999.--

IN THE CLAIMS:

Claim 5 (amended) DNA sequence as defined in claim 1 wherein this DNA sequence is that of the CAtfIIIA gene coding for a protein having the biological function of transcription factor of Candida albicans CATFIIIA containing the nucleotide sequence SEQ ID No: 1.

Claim 7 (amended) DNA sequence of the CAtfIIIA gene according to claim 5 coding for the amino acid sequence SEQ ID No: 3 (412 AA).

Claim 8 (amended) DNA sequence coding for the transcription factor CATFIIIA according to claim 5 as well as DNA sequences which

hybridize with it and/or have a significant homology with this sequence or fragments of it and having the same function.

Claim 9 (amended) DNA sequence according to claim 5 comprising modifications introduced by suppression, insertion and/or substitution of at least one nucleotide coding for a protein having the same biological activity as the transcription factor CATFIIIA.

Claim 10 (amended) DNA sequence according to claim 5 as well as the DNA sequences which have a nucleotide sequence homology of at least 50% or at least 60% and preferably at least 70% with the said DNA sequence.

Claim 11 (amended) DNA sequence according to claim 5 as well as the DNA sequences which code for a protein with a similar function the AA sequence of which has a homology of at least 40% and in particular 45% or at least 50%, rather at least 60% and preferably at least 70% with the AA sequence coded by the said DNA sequence.

Claim 12 (amended) Polypeptide having the transcription factor function CATFIIIA and having the amino acid sequence SEQ ID No: 3 coded by the DNA sequence according to claim 5 and the analogues of this polypeptide.

Claim 13 (amended) Process for the preparation of the recombinant protein CATFIII having the amino acid sequence SEQ ID No: 3 comprising expression of the DNA sequence according to claim 5 in an appropriate host then isolation and purification of the said recombinant protein.

Claim 14 (amended) Expression vector containing the DNA sequence according to claim 5.

Claim 27 (amended) Kit for the diagnosis of fungal infections comprising a DNA sequence as defined in claim 5 or a sequence having a similar function or a functional fragment of this sequence, the polypeptide coded by this sequence or a polypeptide fragment having the same function or an antibody directed against such a polypeptide coded by this DNA sequence or against a fragment of this polypeptide.

Cancel claims 20, 21, 23 and 26 and add the following claims:

--28. A method of treating fungal infections in warm-blooded animals comprising administering to warm-blooded animals in need thereof an antifungally effective amount of a product produced by the process of claim 19.

29. A method of treating diseases caused by Candida albicans yeast in warm-blooded animals comprising administering to warm-blooded animals in need thereof a composition produced by the CAtfIIIA gene or the transcription factor coded by the said gene of claim 5 in an amount sufficient to treat said diseases.--

REMARKS

The amendment is submitted to insert reference to the PCT

application, to remove multiple dependency from the claims and to provide proper method of use claims. Marked up copies of the amended claims are filed herewith.

Respectfully submitted,
Bierman, Muserlian and Lucas

By: _____
Charles A. Muserlian #19,683
Attorney for Applicants
Tel.# (212) 661-8000

CAM:ds
Enclosures

CLAIMS

1) Isolated polynucleotide containing a nucleotide sequence chosen from the following group:

a) a polynucleotide having at least 50 % or at least 60 % and preferably at least 70 % similarity with a polynucleotide coding for a polypeptide with the transcription factor function and having an amino acid sequence homologous with the sequence SEQ ID N°3.

b) a complementary polynucleotide of polynucleotide a).

c) a polynucleotide comprising at least 15 consecutive bases of the polynucleotide defined in a) and b).

2) Polynucleotide according to claim 1 in that this polynucleotide is a DNA.

3) Polynucleotide according to claim 1 in that this polynucleotide is an RNA.

4) Polynucleotide as defined in claim 2 comprising the nucleotide sequence SEQ ID N°1

5) DNA sequence as defined in claim~~s~~ 1~~, 2 and 4 characterized in that~~ wherein this DNA sequence is that of the CAtfIIIA gene coding for a protein having the biological function of transcription factor of Candida albicans CATFIIIA containing the nucleotide sequence SEQ ID N°1

6) DNA sequence according to claim 5 having the sequence starting at nucleotide 720 and finishing at nucleotide 1955 of SEQ ID N°1.

7) DNA sequence of the CAtfIIIA gene according to claim 5 ~~or 6~~ coding for the amino acid sequence SEQ ID N°3 (412 AA).

8) DNA sequence coding for the transcription factor CATFIIIA according to claim~~s~~ 5 ~~to 7~~ as well as DNA sequences which hybridize with it and/or have a significant homology with this sequence or fragments of it and having the same function.

9) DNA sequence according to claim~~s~~ 5 ~~to 8~~ comprising modifications introduced by suppression, insertion and/or substitution of at least one nucleotide coding for a protein having the same biological activity as the transcription factor CATFIIIA.

10) DNA sequence according to ~~one of~~ claim~~s~~ 5 ~~to 9~~ as well as the DNA sequences which have a nucleotide sequence homology of at least 50 % or at least 60 % and preferably at least 70 % with the said DNA sequence.

11) DNA sequence according to ~~one of~~ claim~~s~~ 5 ~~to 10~~ as well as the DNA sequences which code for a protein with a similar function the AA sequence of which has a homology of at least 40 % and in particular 45 % or at least 50 %, rather at least 60 % and preferably at least 70 % with the AA sequence coded by the said DNA sequence.

12) Polypeptide having the transcription factor function CATFIIIA and having the amino acid sequence SEQ ID N°3 coded by the DNA sequence according to ~~one of~~ claim~~s~~ 5 ~~to 11~~ and the analogues of this polypeptide.

13) Process for the preparation of the recombinant protein CATFIII having the amino acid sequence SEQ ID N°3 comprising expression of the DNA sequence according to ~~one of~~ claim~~s~~ 5 ~~to 11~~ in an appropriate host then isolation and purification of the said recombinant protein.

14) Expression vector containing the DNA sequence according to ~~one of~~ claim~~s~~ 5 ~~to 11~~.

15) Host cell transformed with a vector according to claim 14.

16) Process as defined in claim 13 in which the host cell is DH5 alpha E. coli or XL1-Blue E. coli.

17) Process as defined in claim 13 in which the host cell is Saccharomyces cerevisae.

18) Plasmid deposited at the CNCM under the number I-2072.

19) Process of screening antifungal products characterized in that it comprises a stage where the the transcription activity factor of CATFIIIA as defined in claim 12 is measured in the presence of each of the products the antifungal properties of which need to be determined and the products having an inhibitory effect on this activity are selected.

20) Use of a product selected by the process according to claim 19 in order to obtain an antifungal agent.

21) Use of the gene of the transcription factor CAtfIIIA of

Candida albicans or of the transcription factor coded by this gene according to one of claims 5 to 12 for the selection of a product with antifungal properties according to claim 19 as an inhibitor of the transcription factor of Candida albicans.

22) Pharmaceutical compositions containing as active ingredient at least one inhibitor of the transcription factor of Candida albicans as defined in claim 21.

23) Use of compositions as defined in claim 22 as antifungal agents.

24) Method of inducing an immunological response in a mammal comprising the inoculation of this mammal with the polypeptide as defined in claim 12 or a fragment of this polypeptide having the same function in order to produce an antibody making it possible to protect the animal against the disease.

25) Antibody directed against the polypeptide as defined in claim 12 or a fragment of this polypeptide having the same function.

26) Use of the CAtfIIIA gene or of the transcription factor coded by this gene according to ~~one of~~ claim~~s~~ 5 ~~to 12~~ for the preparation of compositions which can be used for the diagnosis or the treatment of diseases caused by the pathogenic yeast Candida albicans.

27) Kit for the diagnosis of fungal infections comprising a DNA sequence as defined in ~~one of~~ claim~~s~~ 5 ~~to 11~~ or a sequence having a similar function or a functional fragment of this sequence, the polypeptide coded by this sequence or a polypeptide fragment having the same function or an antibody directed against such a polypeptide coded by this DNA sequence or against a fragment of this polypeptide.

Candida albicans tfIIIA gene (CatfIIIA) and the coded CATFIIIA protein.

The present invention relates to the Candida albicans transcription factor hereafter called CATFIIIA and its analogues as well as the polynucleotides (RNA, DNA) coding for this protein or for the polypeptide analogues of this protein.

The present invention also relates to the preparation process for these polypeptides and polynucleotides, their use for the study of the transcription mechanisms in Candida albicans and for the preparation of inhibitors of this transcription factor CATFIIIA which can be used as an antifungal agent, and the pharmaceutical compositions containing such inhibitors.

Therefore the present invention in particular relates to a new transcription factor of Candida albicans and the DNA sequence coding for this transcription factor, their preparation and their uses.

We will also use hereafter the following abbreviations: AA for amino acids, NA for nucleic acids, RNA for ribonucleic acid, RNase for ribonuclease, DNA or DNA for deoxyribonucleic acid, cDNA for complementary DNA, bp for base pairs, PCR for polymerase chain reaction, CA or Candida a. for Candida albicans and SC or Saccharomyces c. for Saccharomyces cerevisiae.

The term screening which designates a specific screening technique and the term primer which designates an oligonucleotide used as a primer will also be used.

The term polynucleotide hereafter designates the polynucleotides of the present invention i.e. the DNA sequences and also the RNA sequences coding for the CATFIIIA factor of the present invention and its homologues having the same transcription factor function. The term CAtfIII has the meaning given above for polynucleotides.

The term polypeptides designates hereafter the polypeptides of the present invention i.e. the CATFIIIA factor of the present invention and its functional analogues

or homologues as defined hereafter, thus having the same transcription factor function. The term CATFIII has the meaning given to polypeptides above.

We will call the gene coding for the transcription factor TFIIIA tfIIIA (or tfC2) while CAtfIIIA (or CAtfC2) designates the gene coding for the transcription factor CATFIIIA of Candida albicans.

The range of known fungal infections extends from fungal attack of the skin or nails to more serious mycotic infections of internal organs. Such infections and the diseases which result from them, such as mycosis are identified. Antimycotic substances with fungistatic or fungicidal effects are used for the treatment of these mycoses.

The present invention thus relates to the identification of antimycotic substances and in particular anti-Candida albicans substances.

The present invention thus relates to inhibitors of transcription factors which can be used as antifungal agents. Candida albicans is a pathogenic yeast which causes infectious diseases in the human body. With the aim of finding of a means of treating diseases, intracellular targets can be chosen and the transcription factor TFIIIA can be one of these targets.

In eucaryotic organisms, this factor plays a key role in the initiation of transcription of 5S RNA genes by RNA-polymerase III. In particular for SC which is a similar yeast to CA, it has been shown that this SC yeast could not survive without an additional source of 5S RNA when the chromosomal gene of factor TFIIIA was interrupted, this additional 5S RNA being synthesized using a plasmid without the participation of factor TFIIIA (reference: S. Camier, A.-M. Dechampesme, A. Sentenac./Proc. Natl. Acad. Sci. (1995) 92, 9338-9342).

The tfIIInd gene and the corresponding TFIIIA protein are involved in regulation of the biological transcription mechanism as indicated below.

Since the TFIII protein was purified as transcription factor for the first time in 1980 from Xenopus ovocytes

[Segall and al. Biol. Chem., 255, 11986-11991 (1980)], work has been carried out in vivo and in vitro in the Xenopus in order to study the transcription control mechanism exercized by TFIIIA. It has thus been shown that Xenopus TFIIIA is necessary for the initiation of transcription of the 5S RNA gene [Sakonji and al, Cell 19, 13-25 (1980)] and binds to an internal control region of the 5S RNA gene [Bogenhagen and al, Cell, 19,27-35 (1980)].

The nucleotide sequence of the cDNA of Xenopus TfIIIA and the corresponding amino acid sequence have already been published [Ginberg et al, Cell, 39.479-489 (1984)]. It can be noted that this gene codes for a protein having 9 zinc fingers, a zinc finger corresponding to a moiety containing two cysteines and two histidines linked by a zinc atom (CYS2 HIS2) (C2H2). This zinc finger structure constitutes a linking domain of proteins to the DNA and is therefore considered as an essential domain for a group of proteins which bind to DNA (DNA binding proteins).[Miller et al, Embo J., 4, 1607-1614 (1985)]

It can be noted that other transcription factors binding to DNA which also have this zinc finger structure are known such as for example, in human beings, XT1 of the Wilms human tumor gene, [Gessier et al, Nature, 343, 774-778 (1990)], the human transcription repressor YY1 [Shi et al, Cell, 67, 377-388 (1991)], the MAZ protein combined with the promoter cMYC [Bossone et al, Proc. Natl. Acad. Sci., USA, 89, 7452-7456 (1992)] or also sp1 [Kuwahara et al, J. Biol. Chem, 29, 8627-8631 (1990)].

The study of different organisms such as human beings in particular, the Xenopus or Candida albicans has shown that what can be called a family of TFIIIA transcription factors exist which have the following characteristics:

- they are combined with RNA polymerase III
- they have 9 zinc fingers
- they are indispensable for the transcription of the gene coding for 5S RNA.

A known essential function of the protein coded by the tfIIIA gene (tfC2) in yeast is to initiate the transcription

of the 5S RNA gene in Saccharomyces cerevisiae (Camier et al., Proc. Natl. Acad. Sa USA (1995) 92: 9338-9342).

The present invention has thus made it possible to isolate the DNA and RNA polynucleotides coding for the protein of the transcription factor CATFIIIA of Candida albicans and to reveal their nucleotide sequences.

A subject of the present invention is therefore an isolated polynucleotide containing a nucleotide sequence chosen from the following group:

a) a polynucleotide having at least 50 % or at least 60 % and preferably at least 70 % identity with a polynucleotide coding for a polypeptide having the transcription factor function and having an amino acid sequence homologous with the sequence SEQ ID N°3 indicated hereafter.

b) a complementary polynucleotide of polynucleotide a)

c) a polynucleotide comprising at least 15 consecutive bases of the polynucleotide defined in a) and b).

A subject of the present invention is therefore a polynucleotide defined above in that this polynucleotide is a DNA.

A subject of the present invention is therefore a polynucleotide defined above in that this polynucleotide is an RNA.

A more precise subject of the present invention is the polynucleotide as defined above comprising the nucleotide sequence SEQ ID N°1.

The present invention has thus made it possible to isolate the DNA sequence coding for the transcription factor CATFIIIA of Candida albicans.

The present invention has also made it possible to reveal the nucleic acid sequence of the CAtfIIIA gene and also the amino acid sequence of the CATFIIIA protein coded by this gene.

A subject of the present invention is therefore a DNA sequence as defined by the polynucleotide above, characterized in that this DNA sequence is that of the CAtfIIIA gene coding for a protein having the biological function of transcription factor CATFIIIA of Candida albicans

and containing the nucleotide sequence SEQ ID N°1.
Such a SEQ ID n°1 sequence of the present invention therefore comprises 2060 nucleotides.

A precise subject of the present invention is a DNA sequence as defined above having the sequence starting at nucleotide 720 and finishing at nucleotide 1955 of SEQ ID N°1.

Such a sequence thus comprises 1236 nucleotides.

A subject of the present invention is also the DNA sequence of the CAtfIIIA gene as defined above coding for the amino acid sequence SEQ ID N°3.

The sequence SEQ ID N°3 thus comprises 412 AA.

A particular subject of the present invention is the DNA sequence coding for the transcription factor CATFIII as defined above as well as the DNA sequences which hybridize with it and/or have a significant homology with this sequence or of the fragments of it and having the same function.

A subject of the present invention is also a DNA sequence as defined above, comprising modifications introduced by suppression, insertion and/or substitution of at least one nucleotide coding for a protein with the same biological activity as the transcription factor CATFIIIA.

A particular subject of the present invention is the DNA sequence as defined above as well as DNA sequences which have a nucleotide sequence homology of at least 50 % or at least 60 % and preferably at least 70 % with the said DNA sequence.

Therefore a subject of the present invention is also the DNA sequence as defined above as well as the DNA sequences which code for a protein of similar function, the AA sequence of which has a homology of at least 40 % and in particular 45 % or of at least 50 %, rather at least 60 % and preferably at least 70 % with the AA sequence coded by the said DNA sequence.

By sequences which hybridize, are included the DNA sequences which hybridize with one of the DNA sequences above under standard conditions of high, medium or low stringency and which code for a polypeptide having the same transcription factor function. The stringency conditions are those carried

out under the conditions known to a person skilled in the art such as those described by Sambrook et al, Molecular cloning, Cold Spring Harbor Laboratory Press, 1989. Such stringency conditions are for example hybridization at 65°C, for 18 hours in a 5 x SSPE; 10 x Denhardt's; 100 µg/ml ssDNA; 1 % SDS solution followed by washing 3 times for 5 minutes with 2 x SSC; 0.05 % SDS, then washing 3 times for 15 minutes at 65°C in 1 x SSC; 0.1 % SDS. High stringency conditions include for example hybridization at 65°C for 18 hours in a 5 x SSPE; 10 x Denhardt; 100 µg/ml ssDNA; 1 % SDS solution followed by washing twice for 20 minutes with a 2 x SSC; 0.05 % SDS solution at 65°C, followed by a final washing for 45 minutes in a 0.1 x SSC; 0.1 % SDS solution at 65°C. Medium stringency conditions include for example a final washing for 20 minutes in a 0.2 x SSC, 0.1 % SDS solution at 65°C.

By sequences which have a significant homology, are included sequences with a moderate or high nucleotide sequence similarity with one of the DNA sequences above and which code for a protein having the same transcription factor function.

By similar DNA sequence, is therefore meant DNA sequences which can belong to mycetes other than Candida albicans and in particular to SC, and which are similar or identical to the DNA sequence of the Candida albicans CatfIIIA gene. These similar DNA sequences are not necessarily identical to the DNA sequence of the Candida albicans CatfIIIA gene. The sequence homology at nucleotide level can be moderate or high. The present invention thus relates in particular to DNA sequences which have a nucleotide sequence homology of at least 50 %, preferably at least 60 % and even more preferably at least 70 % with the CAtfIIIA sequence of the present invention.
In addition, these similar DNA sequences do not necessarily code for identical proteins, at the amino acid sequence level, to the protein coded by the CAtfIIIA gene. The present invention therefore relates in particular to DNA sequences which code for proteins said to be homologous, having an amino acid sequence homology of at least 40 %, in

particular 45 %, preferably at least of 50 %, more preferably at least of 60 % and even more preferably at least of 70 % with the protein coded by CAtfIIIA of the present invention.

The gene of the present invention is represented as a single strand DNA sequence as indicated in SEQ ID N°1 but it is understood that the present invention includes the complementary DNA sequence of this single strand DNA sequence and also includes the DNA sequence said to be double stranded constituted by these two DNA sequences complementary to each other.

The DNA sequence as defined above is an example of a combination of codons coding for the amino acids corresponding to the amino acid sequence SEQ ID N°3, but it is also understood that the present invention includes any other arbitrary combination of codons coding for this same amino acid sequence SEQ ID N°3.

For the preparation of polynucleotides and in particular DNA sequences as defined above, modified DNA sequences as indicated above or also homologous DNA sequences as defined above, techniques known to a person skilled in the art and in particular those described in the book by Sambrook, J. Fritsh, E. F. § Maniatis, T. (1989) entitled: 'Molecular cloning: a laboratory manual, Laboratory, Cold Spring Harbor NY can be used.

The homologous DNA sequences as defined above can in particular be isolated according to the methods known to a person skilled in the art for example by PCR technique using degenerated nucleotide primers to amplify these DNA from gene banks or cDNA banks of the corresponding mycetes. The cDNA can also be prepared from mRNA isolated from mycetes of different species studied within the scope of the present invention such as Candida albicans but also for example: Candida stellatoidea, Candida tropicalis, Candida parapsilosis, Candida krusei, Candida pseudotropicalis, Candida quillermondii, Candida glabrata, Candida lusianiae or Candida rugosa or also mycetes such as Saccharomyces cerevisiae or also Aspergillus or Cryptococcus and in particular, for example, Aspergillus fumigatus, Coccidioides

immitis, Cryptococcus neoformans, Histoplasma capsulatum, Blastomyces dermatitidis, Paracoccidioides brasiliens and Sporothrix schenckii type mycetes or also mycetes of the classes of phycomycetes or eumycetes, in particular the sub-classes of basidiomycetes, ascomycetes, mehiascomycetales (yeast) and plectascales, gymnascales (skin and hair fungi) or of the hyphomycetes class, in particular the conidiosporales and thallosporales sub-classes amongst which are the following species: mucor, rhizopus, coccidioides, paracoccidioides (blastomyces, brasiliensis), endomyces (blastomyces), aspergillus, menicilium (scopulariopsis), trichophyton (ctenomyces), epidermophton, microsporon, piedraia, hormodendron, phialophora, sporotrichon, cryptococcus, candida, geotrichum, trichosporon or also toropsulosis.

The polynucleotides of the present invention can thus be obtained by using the usual cloning and screening methods such as those of cloning and sequencing from fragments of chromosomal DNA extracted from cells. For example, in order to obtain the polynucleotides of the present invention, a bank of chromosomal DNA fragments can be used. A probe corresponding to an oligonucleotide labelled with a radioactive element, preferably constituted by 17 or more nucleotides and derived from a partial sequence can be prepared. The clones containing DNA identical to that of the probe can be thus identified under stringent conditions. By the sequencing of the thus identified individual clones, using the sequencing primers originating from the original sequence, it is then possible to extend the sequence in both directions in order to determine the complete gene sequence. In a usual and efficient fashion, such sequencing can be carried out by using denatured double strand DNA prepared from a plasmid. Such techniques are described by Maniatis, T. Fritsch, E.F. and Sambrook as indicated above.(Laboratory Manual, Cold Spring Harbor, New York (1989) (in particular in 1.90 and 13.70 in the chapters of screening by hybridization and sequencing from denatured double strand DNA).

Within the scope of the present invention, a bank of chromosomal DNA fragments of Candida albicans can in particular be used as indicated hereafter in Example 1 in the experimental part.

A detailed description of the operating conditions in which the present invention has been carried out is given below.

A very particular subject of the present invention is the polypeptide having the transcription factor function CATFIIIA and having the amino acid sequence SEQ ID N°3 coded by the DNA sequence as defined above and the analogues of this polypeptide.

By polypeptide analogues, are understood polypeptides, the amino acid sequence of which has been modified by substitution, suppression or addition of one or more amino acids but which retain the same biological function. Such polypeptide analogues can be produced spontaneously or can be produced by post-transcriptional modification or also by modification of the DNA sequence of the present invention as indicated above, using techniques known to a person skilled in the art: Amongst these techniques, the technique of directed mutagenesis known to a person skilled in the art (Kramer, W., et al., Nucl. Acids Res., 12, 9441 (1984); Kramer, W. and Fritz, H.J., Methods in Enzymology, 154, 350 (1987); Zoller, M.J. and Smith, M. Methods in Enzymology, 100, 468 (1983)) can in particular be mentioned.

Modified DNA synthesis can be carried out as indicated above and in particular by using well known chemical synthesis techniques such as for example the phosphotriester method [Letsinger, R.L and Ogilvie, K.K., K. Am. CHEM. Soc., 91, 3350 (1969); Merrifield, R.B., Sciences, 150, 178 (1968)] or the phosphoamidite method [Beaucage, S.L and Caruthers, M .H., Tetrahedron Lett., 22, 1859 (1981); McBRIDE, L.J. and Caruthers, M.H. Tetrahedron Lett., 24 245 (1983)] or also the combination of these methods.

The polypeptides of the present invention can therefore be prepared using techniques known to a person skilled in the art, in particular partially by chemical synthesis or also by

the recombinant DNA technique by expression in a procaryotic or eucaryotic host cell as indicated hereafter.

A particular subject of the present invention is the process for the preparation of the recombinant protein CATFIIIA having the amino acid sequence SEQ ID N°3 comprising the expression of the DNA sequence as defined above in an appropriate host then isolation and purification of the said recombinant protein.

To produce the polypeptide of the present invention, recombinant DNA techniques using genetic engineering and cell culture methods known to a person skilled in the art can in particular be used. The following stages can then be carried out: firstly preparation of the appropriate gene, then incorporation of this gene into a vector, transfer of the carrier vector of the gene into an appropriate host cell, production of the polypeptide by expression of the gene, isolation of the polypeptide, the polypeptide thus produced can then be purified.

The polypeptides of the present invention obtained by expression of the polynucleotides of the present invention can be purified from cell cultures transformed by methods well known to a person skilled in the art such as precipitation with the ammonium sulphate or ethanol, extraction under acid conditions, anion or cation exchange chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and high performance liquid chromatography (HPLC). Techniques well known to a person skilled in the art can be used to regenerate the protein when it is denatured during its isolation or purification.

The DNA sequences according to the present invention and in particular SEQ ID N°1 and SEQ ID N°2 can be prepared according to techniques known to a person skilled in the art in particular by chemical synthesis or by screening of a gene bank or a cDNA bank using synthetic oligonucleotide probes by known hybridization techniques, thus amplification of DNA from isolated fragments or also by reverse transcriptase from messenger RNA (mRNA).

The advantage of the technique comprising firstly the isolation of mRNA by extraction of the total RNA then the synthesis of cDNA from these mRNA by reverse transcriptase in particular rests on the fact that the mRNA do not contain introns even though these non-coding sequences are presented in the genomic DNA.

The usual cloning techniques known to a person skilled in the art and in particular described in the book by Sambrook, J. Fritsh, E. F. § Maniatis, T. (1989) entitled: 'Molecular cloning: a laboratory manual, Laboratory, Cold Spring Harbor NY can then be carried out.
In these techniques, cloning can be carried out by insertion of a fragment into a plasmid which can be provided with a suitable commercial kit then transformation of a bacterial strain by the plasmid thus obtained. In particular the XL1 Blue or DH5 alpha E. coli strain can be used. The clones can then be cultured in order to extract the plasmid DNA according to standard techniques known to a person skilled in the art referred to above (Sambrook, Fritsh and Maniatis). The DNA sequencing of the amplified fragment contained in the plasmid DNA can then be carried out.

The polypeptides of the present invention can be obtained by expression in a host cell containing a polynucleotide according to the present invention and in particular a DNA sequence coding for a polypeptide of the present invention preceded by a suitable promoter sequence. The host cell can be a procaryotic cell, for example E. coli or a eucaryotic cell such as yeast such as for example ascomycetes amongst which is saccharomyces or also mammalian cells such as Cos cells for example.

A particular subject of the present invention is the expression vector containing a DNA sequence as defined above. In the expression vector, such a DNA sequence is therefore in particular the DNA sequence of the CAtfIIIA gene coding for a protein with the biological function of the transcription factor CATFIIIA of Candida albicans containing the nucleotide sequence SEQ ID N°1.
In the expression vector, such a DNA sequence is thus more

particularly the DNA sequence starting with nucleotide 720 and finishing at nucleotide 1955 of SEQ ID N°1.
In the expression vector, such a DNA sequence is thus also more particularly that of the CAtfIIIA gene as defined above coding for the amino acid sequence SEQ ID N°3.
In the expression vector, such a DNA sequence is thus a DNA sequence as defined above coding for the transcription factor CATFIIIA as well as the DNA sequences which hybridize with it and/or have a significant homology with this sequence or fragments of it, or also DNA sequences comprising modifications introduced by suppression, insertion and/or substitution of at least one nucleotide coding for a protein having the same biological activity as the transcription factor CATFIIIA.
In the expression vector, such a DNA sequence is in particular a DNA sequence as defined above as well as similar DNA sequences which have a nucleotide sequence homology of at least 50 % or at least 60 % and preferably at least 70 % with the said DNA sequence or also similar DNA sequences which code for a protein, the AA sequence of which has a homology of at least 40 % and in particular of 45 % or of at least 50 %, rather at least 60 % and preferably at least 70 % with the AA sequence coded by the said DNA sequence.
The expression vectors are vectors allowing the expression of the protein under the control of a suitable promoter. Such a vector can be a plasmid, a cosmid or viral DNA. For the procaryotic cells, the promoter can for example be the lac promoter, the trp promoter, the tac promoter, the β-lactamase promoter or the PL promoter. For the yeast cells, the promoter can be for example the PGK promoter or the GAL promoter. For mammalian cells, the promoter can for example be the SV40 promoter or adenovirus promoters.

Baculovirus type vectors can be also used for the expression in insect cells.

The host cells are for example procaryotic cells or eucaryotic cells. The procaryotic cells are for example E. coli, Bacillus or Streptomyces. The eucaryotic host cells include yeasts as well as of the cells of higher organisms,

for example mammalian cells or insect cells. The mammalian cells are for example fibroblasts such as hamster CHO or BHK cells and monkey Cos cells. The insect cells are for example SF9 cells.

The present invention therefore relates to a process which comprises the expression of a polynucleotide according to the present invention coding for the CATFIIIA protein in a host cell transformed by a polynucleotide according to the present invention and in particular a DNA sequence coding for the amino acid sequence SEQ ID N°3. In the implementation of such a process, the host cell is in particular a eucaryotic cell.

For the implementation of the present invention, the vectors used can for example be pGEX or pBAD and the host cell can be E. coli or for example the vector pYX222 and the host cell can be in particular Saccharomyces cerevisiae.

A particular subject of the present invention is the host cell transformed with a vector as defined above and containing a DNA sequence according to the present invention.

A subject of the present invention is therefore the process for the preparation of a recombinant protein according to the present invention, as defined above, in which the host cell is DH5 alpha E. coli or XL1-Blue E. coli or in particular Saccharomyces cerevisiae.

A detailed account of the conditions under which the operations indicated above can be carried out is given hereafter in the experimental part. A plasmid is thus obtained in which the gene of the present invention is inserted and this plasmid introduced into a host cell is then obtained by operating according to the usual techniques known to a person skilled in the art.

A very precise subject of the present invention is the plasmid deposited at the CNCM under the number I-2072.

It therefore particularly relates to the XL1-Blue/Yep24-Catfc2 strain containing the CAtfIIIA gene according to the present invention.

This gene corresponds therefore to the sequence 720-1955 of SEQ ID N°1.

The operating conditions under which the present invention was carried out are described hereafter in the experimental part.

The TFIIIA protein coded by the CAtfIIIA gene is therefore a transcription factor. In fact, the TFIIIA protein coded by the gene of the present invention has a biological role as a protein binding to the DNA and would be useful as transcription factor.

In particular, the gene of the present invention is expressed in different tissues and plays an important role in the initiation of the transcription of the 5s ribosomal RNA gene. The study of these factors can also be useful in the analysis of transcription regulation mechanisms.

A subject of the present invention is therefore a process for screening antifungal products characterized in that it comprises a stage where the activity of transcription factor CATFIIIA as defined above is measured in the presence of each of the products whose antifungal properties need to be determined and the products with an inhibitory effect on this activity are selected.

The demonstration within the scope of the present invention of the functional homology of the transcription factors of Candida albicans and Saccharomyces cerevisiae, illustrated in the experimental part hereafter, make it possible to envisage numerous applications for the transcription factor CATFIIIA of the present invention.

In particular because of the fact that it appears that the activity of SCTFIIIA is essential for cell survival, substances which inhibit this activity can be used as antifungal agents, either as medicaments or at an industrial level.

For example, to screen antifungal substances such as substances active on Candida albicans, the activity of CATFIIIA or one of its functional homologues constituted by a TFIIIA transcription factor is measured in the presence of each of the products whose antifungal properties need to be determined and the products having an inhibitory effect on this activity are selected.

Such screening can be carried out by measuring the transcription activity of TFIIIA in the presence of activators or of potential inhibitors to be tested. The transcription of 5S RNA can for example be measured in vitro directly by detecting the synthesis of the 5S RNA in an appropriate reaction medium.

The transcription activity can also be measured in vivo by a cell viability test. For example, transcription activity can be favourably measured in mutant Saccharomyces cerevisiae cells not expressing SC TFIIIA transformed by the CAtfIIIA gene.

The invention also encompasses the use of a product selected as indicated above for its properties of inhibiting a TFIIIA transcription factor in order to obtain of an antifungal agent.

The present invention will be better understood by reference to the experimental part which follows and which describes the cloning of the CAtfIIIA gene of the present invention.

A subject of the present invention is thus the use of a product selected by the process of screening antifungal products as defined above in order to obtain an antifungal agent.

A subject of the present invention is also the use of the transcription factor CAtfIIIA gene of Candida albicans or the transcription factor coded by this gene as defined above for the selection of a product having antifungal properties as defined above and used as inhibitor of the transcription factor of Candida albicans.

A subject of the present invention is also pharmaceutical compositions containing at least one inhibitor of the transcription factor of Candida albicans as defined above as active ingredient.

Such compositions can in particular be useful for treating topical and systemic fungal infections.

The pharmaceutical compositions indicated above can be administered by oral, rectal, parenteral route or by local route as a topical application on the skin and mucous

membranes or by injection, by intravenous or intramuscular route. These compositions can be solid or liquid and be presented in all the pharmaceutical forms currently used in human medicine such as, for example, plain or sugar coated tablets, gelatin capsules, granules, suppositories, injectable preparations, ointments, creams, gels and aerosol preparations; they are prepared according to usual methods. The active ingredient can be incorporated in excipients normally used in these pharmaceutical compositions, such as talc, gum arabic, lactose, starch, magnesium stearate, the cocoa butter, aqueous or non aqueous vehicles, fatty substances of animal or vegetable origin, paraffin derivatives, glycols, various wetting, dispersing or emulsifying agents, and preservatives.

The dose will be variable according to the product used, the subject treated and the disease in question.

A particular subject of the present invention is thus the use of compositions as defined above such as antifungal agents.

A subject of the present invention is also a method of inducing an immunological response in a mammal comprising the inoculation of this mammal with the polypeptide according to the present invention as defined above or a fragment of this polypeptide having the same function in order to produce an antibody protecting the animal against the disease.

A subject of the present invention is therefore antibodies directed against the polypeptides of the present invention as defined above having the transcription factor function CATFIIIA or against a fragment of these polypeptides having the same function and coded by the polynucleotides of the present invention and in particular by a DNA sequence as defined above.

The polypeptides of the present invention can thus be used as immunogens to produce immunospecific antibodies of these polypeptides. The term antibody designates antibodies which can equally be monoclonal, polyclonal, chimeric, single chain, non-human antibodies and human antibodies, as well as Fab fragments, including the products of a Fab immunoglobulin

bank. The antibodies produced against the polypeptides of the present invention can be obtained by administration of the polypeptides of the present invention or fragments carrying epitopes, their analogues or also animal cells, preferably non-human, by using routine protocols for the preparation of monoclonal antibodies. Such antibodies can be prepared by methods well known in this field such as those described in the book Antibodies, Laboratory manual Ed. Harbow and David Larre, Cold Spring Harbor laboratory Eds, 1988.

A very particular subject of the present invention is thus an antibody directed against the CATFIIIA protein of the present invention or a fragment of this protein in particular having the same function.

A subject of the present invention is also the use of the CAtfIIIA transcription factor gene or the transcription factor coded by this gene as defined above for the preparation of compositions which can be used for the diagnosis or treatment of diseases caused by the pathogenic yeast Candida albicans.

The present invention also relates to the use of the polynucleotides of the present invention as diagnostic reagents. The detection of a polynucleotide according to the present invention coding for the TFIIIA protein of Candida albicans or of its analogues in a eucaryotic cell in particular a mammalian cell and more particularly a human being, can constitute a means of diagnosing a disease: thus, such a polynucleotide according to the present invention and in particular a DNA sequence can be detected by a wide variety of techniques in a eucaryotic cell in particular a mammal and more particularly a human being, infected by an organism containing at least one of the polynucleotides of the present invention. The nucleic acids for such a use as a diagnostic tool can be detected in infected cells or tissues, such as bone, blood, muscle, cartilage or skin. For this detection, the genomic DNA can be used directly or also be amplified by PCR or another amplification technique. The RNA or DNA and cDNA can also be used with the same purpose. By

amplification techniques, the line of the mycete present in a eucaryote in particular a mammal and more particularly a human being, can be characterized by analysis of the genotype. Deletions or insertions can be detected by a change in the size of the amplified product in comparison with the genotype of the reference sequence. The points of mutation can be identified by hybridization of the DNA amplified with the sequences, labelled by a radioactive element, of polynucleotides of the present invention. Perfectly complementary sequences can therefore be distinguished from the duplex which poorly resist digestion by nucleases. The DNA sequence differences can also be detected by alterations in the electrophoretic mobility of DNA fragments in gels, with or without denaturing agent, or by direct DNA sequencing (reference: Myers et al. Science, 230: 1242 (1985)). Sequence changes at specific locations can also be revealed by protection experiments against nucleases such as RNase I and S1 or by chemical cleavage methods (reference: Cotton et al., Proc Natl Acad Sci, USA, 85: 4397-4401 (1985).

Cells containing one of the polynucleotides of the present invention carrying mutations or polymorphisms can also be detected by a large number of techniques making it possible in particular to determine the serotype. For example, the RT-PCR technique can be used to detect the mutations. It is particularly preferable to use RT-PCR techniques in conjunction with automatic detection systems, such as for example the GeneScan technique. RNA and cDNA can be used in the PCR or RT-PCR techniques. For example, complementary primers of polynucleotides coding for the polypeptides of the present invention can be used to identify and analyse the mutations.

Primers can therefore be used to amplify an isolated DNA from the infected individual. In this way mutations in the DNA sequence can be detected and used to diagnose the infection and determine the serotype or the classification of the infectious agent. Such techniques are standard for a person skilled in the art and are described in particular in the manual 'Current Protocols in Molecular Biology', Ausubel et

al, ed. John Wiley § sons, Inc., 1995).

The present invention therefore relates to a process of diagnosing a disease and preferably a fungal infection caused in particular by Candida albicans such as mycoses as indicated above, this process comprising the determination from a sample taken from an infected individual, an increase in the quantity of polynucleotide of the present invention. Such a polynucleotide can in particular have a DNA sequence of the present invention as defined above.

Increases or reductions in the quantity of polynucleotides can be measured by techniques well known to a person skilled in the art such as in particular amplification, PCR, RT PCR, Northern blotting or other hybridization techniques.

In addition, a diagnosis method in accordance with the present invention consists of the detection of too large an expression of polypeptides of the present invention, in comparison with control samples constitued by normal, non-infected tissues used to detect the presence of an infection. The techniques which can therefore be used to detect the quantities of proteins expressed in a host cell sample are well known to a person skilled in the art. For example the radioimmunoassay or competitive-binding techniques, Western Blot analysis and ELISA test (ref Ausubel indicated above) can thus be mentioned.

A subject of the present invention is also a kit for the diagnosis of fungal infections comprising a DNA sequence according to the present invention as defined above or a sequence having a similar function or a functional fragment of this sequence, the polypeptide coded by this sequence or a polypeptide fragment having the same function or an antibody directed against such a polypeptide coded by this DNA sequence or against a fragment of this polypeptide.

This kit can thus contain a DNA sequence according to the present invention as defined above and for example the DNA sequence SEQ ID N°1 or a fragment of this sequence or also the sequence 720 to 1955 of SEQ ID N°1.

Such kit could also contain a polypeptide according to the present invention or a fragment of this polypeptide and in

particular the protein having the AA sequence SEQ ID N°3 or also an antibody as defined above.

Such a kit can be prepared according to methods well known to a person skilled in the art.

The sequences SEQ ID N° 1 to 9 indicated in the present invention are described hereafter.

The experimental part hereafter makes it possible to describe the present invention without however limiting it.

Experimental part

Example 1: Cloning and sequencing of the CAtfIIIA gene

a) Culture Conditions:

The bacteria Escherichia coli (E. coli) of the DH5 alpha (Gibco BRL) or XL1- Blue type K12 (Stratagene) line was used for the preparation of the plasmids of the present invention.

The growth of this bacteria was carried out according to usual conditions in liquid LB medium which contains 10 g of bactotryptone, 5 g of yeast extract and 10 g of NaCl per litre of water and which also contains 100 micro g/ml of ampicillin (SIGMA).

The colony was removed onto solid LB + agar + ampicillin medium then cultivated in 100 ml of LB medium and incubated to OD (600 nm) = 0.8.

The incubation was carried out at 37°C under a normal atmosphere and agitation at 225 rpm.

The viability of the strain is verified when the strain grows on LB + ampicillin medium at 100 micro g/ml.

It can be noted that a gene resistant to the Bla ampicillin forms part of the vector in which the fragments of CAtfIIIA are cloned. Therefore, the selection of strains containing the plasmids containing the tfIIIA gene of Candida albicans of the present invention can be carried out by culture of the strains in this medium containing ampicillin (100 micro g/ml), such a medium only allowing the survival of strains which contain the gene resistant to the ampicillin and therefore only strains which contain the tfIIIA gene of Candida a. of the present invention.

For the preservation of the strains obtained, 15 % of glycerol is added to the culture medium: the cultures are

therefore preserved in the suspension medium LB +100 micrograms/ml of ampicillin + 15 % of glycerol at the bacterial concentration of OD (600 nm = 0.8 in the form of aliquots in cryotubes of 1 ml per tube.

For the sequencing, the plasmid DNA of several bacteria originating from each of the cloning operations indicated hereafter is prepared using a commercial kit (Qiagen Plasmids kit). The fragments corresponding to the sequence of the CAtfIIIA gene are sequenced on the two strands according to standard techniques known to a person skilled in the art (use of the ABI 377 XL sequencer, Perkin Elmer).

b) Cloning and sequencing of the CAtfIIIA gene:

Within the scope of the present invention, the gene coding for the transcription factor CA i.e. SEQ ID N°1 represented in Figure 1 was isolated from the gene fragment bank of Candida albicans. (Sanglard et al., Antimicrobial agents and chemotherapy 39, 2378-2386, (1995)).

The structure of the gene was identified by sequencing.

The strategy used rests on the hypothesis that SC and CA are similar yeasts the gene structure of which can be homologous.

The following process is then carried out:

Within the scope of the present invention, by using the Standford internet site which makes it possible to access the preliminary sequences of the Candida albicans genome, a fraction of sequence homologous with S. cerevisiae tfIIIA was identified. This fragment contains an open reading frame (258 bp) coding for a protein for which two zinc finger moieties and a region rich in serine residues characteristic of the TFIIIA factor of SC can be identified. This open reading frame in reality contains 259 nucleotides. In order to amplify the fragment corresponding to Candida albicans, two oligonucleotides were selected from this sequence. These oligonucleotides are the following:

INT CAND located in the position 720-740 of SEQ ID N°1 and called SEQ ID N°4 and

3' CAND located in the position 955-978 of SEQ ID N°1 and called SEQ ID N°5.

A fragment of 259 base pairs is thus obtained.

It was firstly confirmed by PCR that it is possible to amplify a fragment of CA genomic DNA, prepared from CA cells by the usual methods known to a person skilled in the art, and on the other hand in the CA gene bank. These oligonucleotides have also made it possible to synthesize a fragment of DNA from genomic DNA of Candida albicans in order to prepare a probe labelled with 32P (phosphorus 32) using a kit (Mega Prime, Amersham).

This fragment was used for the screening of the bank of genomic Sau 3A fragments of Candida albicans cloned in the BamHI site of the vector YEp24 (multicopy-Ura3) [Botstein et al., Gene, 8, 17-24, (1979)].

The DH5 alpha E. coli cells transformed with the vector YEp24 (multicopy vector with selection gene URA3) containing the fragments described above (17000 clones) are plated on dishes containing a LB + ampicillin medium and cultured at 37°C. A replica on nitrocellulose filter is then treated by techniques known to a person skilled in the art such as for example NaOH: 0.5M, 5 minutes; Tris-HCl: 1M (pH = 7.5) 5 minutes; NaCl 1.5M/Tris-HCl 0.5M (pH 7.5).

As regards drying, the filters are kept for 10 minutes at 80°C then fixed with UV (Stratalinker). Pre-hybridization and hybridization are carried out in a NaPO4 buffer (pH 7.2) 0.5M; EDTA 10mM; SDS 7 % (ref., Church and Gilbert, PNAS 81: 1991 (1984)).

The probe is labelled with 32P with the MegaPrime and (alpha 32P) dCTP kit (Amersham UK). The hybridization is carried out overnight at 65°C. The filters are then washed in 1 % SDS, 40 mM NaPO4 (pH 7.2), six times for 5 minutes at 65°C and they are then subjected to autoradiography overnight. Hybridization on a filter with the probe labelled with 32P has made it possible to select several positive clones which have been recultured in dishes in order to isolate them. Individual clones have thus been isolated.

Three types of clones are thus obtained which are called 9, 18 and 47 containing three different inserts of the CAtfIIIA gene of the present invention: analysis by PCR confirmed the presence of the 259 bp fragment.

The YEp24 plasmids containing Candida albicans inserts were collected from these colonies. The restriction map of each of these plasmids was established and made it possible to note that all the inserts originate from the same region of the Candida albicans genome. For the sequencing of this region the following oligonucleotides were used:

INT-Cand located at position: 720-740 of SEQ ID N°1 and called SEQ ID N°4

3'-Cand located at position: 955-978 of SEQ ID N°1 and called SEQ ID N°5

Cont-Int located at position: 719-741 of SEQ ID N°1 and called SEQ ID N°6

Can-Kor1 located at position 1365-1389 of SEQ ID N°1 and called SEQ ID N°7

and the sequencer ABI 377 XL (Perkin Elmer). The sequencing of this region made it possible bring the following points to light:

1) The three clones all contain only one open reading frame, uninterrupted for 1236 bp with the same sequence which codes for a protein.

2) The open reading frame codes for a 412 AA protein which shows a significant homology with the TFIIIA factor of Saccharomyces cerevisiae. Analysis of the protein makes it possible to find the 9 zinc finger moieties which are characteristic of the transcription factor TFIIIA. Comparison of the proteinic sequences of SC CATFIIIA and TFIIIA, makes it possible to demonstrate a similarity of 50 % and an identity of 45 %. For the amino acid translation the fact that in Candida albicans the CTG codon is translated to serine and that there are 2 CTG codons in Candida albicans TFIIIA was taken into account.

The following should be noted:

- The preservation of the Serine rich region in the N-terminal part.
- the presence of a very long intermediate region between the 8 and 9 zinc fingers characteristic of SC.

The sequence differences between the TFIIIA proteins of SC and TFIIIA of Candida albicans is located in the C-terminal

part outside the zinc finger moieties.
The YEp24 plasmid containing the promoter region and the sequence coding for CATFIII was transformed in the XL1 Blue E. Coli strain then deposited under the number I-2072 at the CNCM, Institut Pasteur 25 rue of Docteur ROUX 75015 Paris, on the 15th September 1998.

Example 2: expression of the tfIIIA gene

A fragment contained in clone 9 was amplified by PCR using primers containing sequences recognized by the restriction enzymes EcoRI and XhoI and hybridizing with the tfC2 gene, the primers are the following:
5-EcoTF located at position 720-732 of SEQ ID N°1 and called SEQ ID N°8 and
3'-XhoI located at position 1946-1960 of SEQ ID N°1 and called SEQ ID N°9.
Amplification by PCR of the genomic DNA is then carried out in the following manner:
0.5 micrograms of DNA of clone 9 is added to 50 microlitres of a reaction solution containing 200 nanograms/ml of each dNTP, the primers indicated above at a rate of 25 micromoles/l for each, 2mM MgCl2, 1 x Pfu Buffer, 5U Pfu polymerase (Perkin Elmer).
The reaction medium is subjected to 30 PCR cycles each corresponding to 94°C for 30 seconds, then 60°C for 45 seconds then 72°C for 1 minute.
The fragment containing the coding sequence for CATFIII was sub-cloned in the vectors pYX122 (CEN, HIS 3) and pYX222 (2 micron, HIS3) (R and D System). This plasmid was used to transform Saccharomyces c cells. YWRI (Mat alpha, can 1-100, his 3-11, leu 2-3, 112 trp 1-1, ura 3-1, ade 2-1, tfC2: leu2 + pJA230), (Camier and al, Proc. Natl. Acad. Sci. 92 9338-9342, 1995).
The strain transformed according to the same methods as those indicated above allows the expression of the transcription factor TFIIIA of Candida albicans containing a HA tag.
Conclusion
The experimental implementations indicated above therefore show the following points:

1) The TFIIIA factor gene of Candida albicans was isolated in three clones 9, 18 and 47 obtained as indicated above in Example 1 from the gene bank of Candida albicans using a hybridization technique. The structure of this gene was identified by sequencing.

2) The CATFIIIA protein of the CAtfIIIA gene obtained in Example 1 is constituted by 412 AA and shows a high homology with the SC TFIIIA factor. This protein contains a region rich in SER residues in the N-terminal and 9 zinc finger part, the arrangement of which is identical to that of the TFIIIA protein of SC.

3) The sub-cloning of the gene of the TFIIIA factor of Candida albicans was carried out and the gene was placed under the control of an SC promoter.

CLAIMS

1) Isolated polynucleotide containing a nucleotide sequence chosen from the following group:

a) a polynucleotide having at least 50 % or at least 60 % and preferably at least 70 % similarity with a polynucleotide coding for a polypeptide with the transcription factor function and having an amino acid sequence homologous with the sequence SEQ ID N°3.

b) a complementary polynucleotide of polynucleotide a).

c) a polynucleotide comprising at least 15 consecutive bases of the polynucleotide defined in a) and b).

2) Polynucleotide according to claim 1 in that this polynucleotide is a DNA.

3) Polynucleotide according to claim 1 in that this polynucleotide is an RNA.

4) Polynucleotide as defined in claim 2 comprising the nucleotide sequence SEQ ID N°1

5) DNA sequence as defined in claims 1, 2 and 4 characterized in that this DNA sequence is that of the CAtfIIIA gene coding for a protein having the biological function of transcription factor of Candida albicans CATFIIIA containing the nucleotide sequence SEQ ID N°1

6) DNA sequence according to claim 5 having the sequence starting at nucleotide 720 and finishing at nucleotide 1955 of SEQ ID N°1.

7) DNA sequence of the CAtfIIIA gene according to claim 5 or 6 coding for the amino acid sequence SEQ ID N°3 (412 AA).

8) DNA sequence coding for the transcription factor CATFIIIA according to claims 5 to 7 as well as DNA sequences which hybridize with it and/or have a significant homology with this sequence or fragments of it and having the same function.

9) DNA sequence according to claims 5 to 8 comprising modifications introduced by suppression, insertion and/or substitution of at least one nucleotide coding for a protein having the same biological activity as the transcription factor CATFIIIA.

10) DNA sequence according to one of claims 5 to 9 as well as the DNA sequences which have a nucleotide sequence homology of at least 50 % or at least 60 % and preferably at least 70 % with the said DNA sequence.

11) DNA sequence according to one of claims 5 to 10 as well as the DNA sequences which code for a protein with a similar function the AA sequence of which has a homology of at least 40 % and in particular 45 % or at least 50 %, rather at least 60 % and preferably at least 70 % with the AA sequence coded by the said DNA sequence.

12) Polypeptide having the transcription factor function CATFIIIA and having the amino acid sequence SEQ ID N°3 coded by the DNA sequence according to one of claims 5 to 11 and the analogues of this polypeptide.

13) Process for the preparation of the recombinant protein CATFIII having the amino acid sequence SEQ ID N°3 comprising expression of the DNA sequence according to one of claims 5 to 11 in an appropriate host then isolation and purification of the said recombinant protein.

14) Expression vector containing the DNA sequence according to one of claims 5 to 11.

15) Host cell transformed with a vector according to claim 14.

16) Process as defined in claim 13 in which the host cell is DH5 alpha E. coli or XL1-Blue E. coli.

17) Process as defined in claim 13 in which the host cell is Saccharomyces cerevisae.

18) Plasmid deposited at the CNCM under the number I-2072.

19) Process of screening antifungal products characterized in that it comprises a stage where the the transcription activity factor of CATFIIIA as defined in claim 12 is measured in the presence of each of the products the antifungal properties of which need to be determined and the products having an inhibitory effect on this activity are selected.

20) Use of a product selected by the process according to claim 19 in order to obtain an antifungal agent.

21) Use of the gene of the transcription factor CAtfIIIA of

Candida albicans or of the transcription factor coded by this gene according to one of claims 5 to 12 for the selection of a product with antifungal properties according to claim 19 as an inhibitor of the transcription factor of Candida albicans.

22) Pharmaceutical compositions containing as active ingredient at least one inhibitor of the transcription factor of Candida albicans as defined in claim 21.

23) Use of compositions as defined in claim 22 as antifungal agents.

24) Method of inducing an immunological response in a mammal comprising the inoculation of this mammal with the polypeptide as defined in claim 12 or a fragment of this polypeptide having the same function in order to produce an antibody making it possible to protect the animal against the disease.

25) Antibody directed against the polypeptide as defined in claim 12 or a fragment of this polypeptide having the same function.

26) Use of the CAtfIIIA gene or of the transcription factor coded by this gene according to one of claims 5 to 12 for the preparation of compositions which can be used for the diagnosis or the treatment of diseases caused by the pathogenic yeast Candida albicans.

27) Kit for the diagnosis of fungal infections comprising a DNA sequence as defined in one of claims 5 to 11 or a sequence having a similar function or a functional fragment of this sequence, the polypeptide coded by this sequence or a polypeptide fragment having the same function or an antibody directed against such a polypeptide coded by this DNA sequence or against a fragment of this polypeptide.

Please type a plus sign (+) inside this box → [+]

PTO/SB/01 (8-96)
Approved for use through 9/30/98 OMB 0651-0032
Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION

Attorney Docket Number	146.1365
First Named Inventor	F. BORDON-PALLIER
COMPLETE IF KNOWN	
Application Number	PCT/FR99/02739
Filing Date	11/9/99
Group Art Unit	
Examiner Name	

[X] Declaration Submitted with Initial Filing OR [ ] Declaration Submitted after Initial Filing

OLP JUL 23 2001 PATENT & TRADEMARK OFFICE

As a below named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

CANDIDA ALBICANS TFIIIA GENE (CatfIIIA) AND THE CODED CATFIIIA PROTEIN

(Title of the Invention)

the specification of which

[ ] is attached hereto

OR

[X] was filed on (MM/DD/YYYY) Nov. 9, 1999 as United States Application Number or PCT International

Application Number PCT/FR99/02739 and was amended on (MM/DD/YYYY) (if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37 Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35 United States Code §119 (a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or §365 (a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached? YES	Certified Copy Attached? NO
98/14147	France	11/10/98	[ ]	[ ]	[ ]
PCT/FR99/02739	France	11/9/99	[ ]	[ ]	[ ]
			[ ]	[ ]	[ ]
			[ ]	[ ]	[ ]
			[ ]	[ ]	[ ]
			[ ]	[ ]	[ ]

[ ] Additional foreign application numbers are listed on a supplemental priority sheet attached hereto:

I hereby claim the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date (MM/DD/YYYY)

[ ] Additional provisional application numbers are listed on a supplemental priority sheet attached hereto.

Please type a plus sign (+) inside this box → [+]

PTO/SB/01 (4-98)
Approved for use through 9/30/98. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION

I hereby claim the benefit under Title 35, United States Code §120 of any United States application(s), or §365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application Number	PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	Parent Patent Number (if applicable)

☐ Additional U.S. or PCT international application numbers are listed on a supplemental priority sheet attached hereto.

As a named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Name	Registration Number	Name	Registration Number
Charles A. Muserlian	19,683		
Jordan B. Bierman	18,629		
Donald C. Lucas	31,275		
Bierman, Muserlian and Lucas	18,818		

☐ Additional registered practitioner(s) named on a supplemental sheet attached hereto.

Direct all correspondence to:

Name: Bierman, Muserlian and Lucas

Address:

Address: 600 Third Avenue

City: New York | State: New York | ZIP: 10016

Country: U.S.A. | Telephone: (212) 661-8000 | Fax: (212) 661-8002

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name of Sole or First Inventor: ☐ A petition has been filed for this unsigned inventor

Given Name	Middle Initial	Family Name	Suffix e.g. Jr.
FLORENCE		BORDON-PALLIER	

Inventor's Signature: [signature] Date: 23 April 2001

Residence: City: Guyancourt | State: | Country: France FR X | Citizenship: FR

Post Office Address:

Post Office Address: 37, Boulevard Beethoven

City: Guyancourt | State: | Zip: F-78280 | Country: France

☒ Additional inventors are being named on supplemental sheet(s) attached hereto

Please type a plus sign (+) inside this box → + 146.1365

PTO/SB/01 (8-96)
Approved for use through 9/30/98. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION

ADDITIONAL INVENTOR(S)
Supplemental Sheet

Name of Additional Joint Inventor, if any: ☐ A petition has been filed for this unsigned inventor

Given Name	Middle Initial	Family Name	Suffix e.g. Jr.
SYLVIE		CAMIER	

Inventor's Signature: [signature] Date: 15 Mai 2001

Residence: City	State	Country	Citizenship
Piemont	CA	USA	FR/US

Post Office Address: 66, Oakmont Avenue

City	State	Zip	Country
Piemont	CA	94610	USA

300

Name of Additional Joint Inventor, if any: ☐ A petition has been filed for this unsigned inventor

Given Name	Middle Initial	Family Name	Suffix e.g. Jr.
ANDRE		SENTENAC	

Inventor's Signature: [signature] Date: 4 Mai 2001

Residence: City	State	Country	Citizenship
Gif sur Yvette		France FR X	FR

Post Office Address: Service de Biochimie et Genetique Moleculaire Bat

Post Office Address: 142 CEA/SACLAY

City	State	Zip	Country
Gif sur Yvette		F-91191	France

Name of Additional Joint Inventor, if any: ☐ A petition has been filed for this unsigned inventor

Given Name	Middle Initial	Family Name	Suffix e.g. Jr.

Inventor's Signature: Date:

Residence: City	State	Country	Citizenship

Post Office Address:

Post Office Address:

City	State	Zip	Country

Name of Additional Joint Inventor, if any: ☐ A petition has been filed for this unsigned inventor

Given Name	Middle Initial	Family Name	Suffix e.g. Jr.

Inventor's Signature: Date:

Residence: City	State	Country	Citizenship

Post Office Address:

Post Office Address:

City	State	Zip	Country

☐ Additional inventors are being named on supplemental sheet(s) attached hereto

SEQUENCE LISTING

<110> Hoechst Marion Roussel

<120> Candida albicans tfIIIA gene (CAtfIIIA) and the coded CATFIIIA protein.

<130> PATENT 9824

<140>
<141>

<160> 9

<170> PatentIn. 2.0

<210> 1
<211> 2060
<212> DNA
<213> Candida albicans

<400> 1
ctttattagg aagattggct aggccatttt gtattacggg tctccaaagt gcaattgttt 60

tagtaaatat ccaatcattg ggcttcagtg tgaatggggg ttgtcaatct cttggtgtag 120

aaataggcgc aggcctccga atcccaaaaa aagaagaatc aggatgtctc ggctgcaaga 180

tttgtagcca tggcaaatgc cgaaaaatga aaaaaaaaaa aaagtctact gggcccacct 240

acaaaaggaa aagtgattga actagatcag tagtggtctg gaccctctat aattttataa 300

tattgtcacg ggctttagaa tttgtataat tgtgtgtctg acactctgtg gttaatatct 360

ggacatctcg ttccccttgt gaagggtcgt ctgtaatgaa ttcatgatca agaataatat 420

gactttgctc acttcataga gtgccgactt gattattatt gagctttatc ctctgtaata 480

tatcgtaacc acttgactta tttccttgtt gtgggattca ctttggatga tgatgttaac 540

caaatgtaat tggtacaatc ctttttgtcc ttgtcgcgac ttcctttaat atcgcgactt 600

atttcattaa tgagacgcaa cgcattcctc tctccataga aaaaaaaaat aacaaactga 660

aaaaataaac agcggacctc atctcttttt ttcaaatcca ctttttatta ctttattcaa 720

tgagtgaaag tgacgaaacc aaatcgatat catctttaat atcttcttct tcttcatcac 780

gtcccaaaaa gtatatttgc acatatgaag ggtgtgataa agcctataat cgaccatcat 840

tattagagca acatttaaga acccacagta atgatcgacc gtataaatgt acagtggacg 900

attgtgataa agcatttttc agaaaatcac atttggaaac acatattgta tcacattccg 960

aaaaaaaacc attccattgt tcagtgtgtg gtaaaggggt taattctcga caacacttga 1020

aaagacatga aatcacccat acaaagtcat ttaaatgtac atttgaaaat tgtcaagaag 1080

cattttataa acatcaatct ttaagacatc atatattatc tgttcatgaa aaaacattaa 1140

cgtgtaaaca atgtaataaa gttttcactc gaccttcaaa attagcacaa cataaattaa 1200

aacatcatgg tggatctcct gcttatcaat gtgatcatcc tggttgtttt aaaaatttcc 1260

aaacttggtc agtattacaa tttcatataa aacaactgca tccaaaactt aaatgtccta 1320

aatgtggtaa aggttgtgtt gggaaaaaag gtttatcttc acatatgtta agtcatgatg 1380

attctaccat gatcaaaata tggacttgtg attattgtga tgtggggaaa tttgcaaaga 1440

aaaatgaatt agttgaacat tataatatct tccatgatgg taatatccct gatgatttat 1500

taaaggaaac tgaagtgaaa aaattagaga acctattaga tcaaggatcg aaattaaata 1560

atttgcatga attagaaaca gagaaattaa aagtggaaga agatgaagaa gatgaagaag 1620

atagtctaga tgaaaaaaga agtgatgtta gatcagactc aatgtcagct caaagatcaa 1680

taaaatcatt tactgcttct ttggaaggtt caaagagtgt ttctaaactt attctgaata 1740

gtgggaagaa gatcaattgt cctaagaata attgtgatag aatgttttct agagaatatg 1800

atttacgtcg acatttgaaa tggcatgatg ataatttaca aagaattgag tcattcttaa 1860

atagtataga aaaagaagaa actccagaag gtgaaccatt ggttaaaaaa gccaggatgg 1920

atttattgcc aaatgaaaca tcagtgattt ctcgataata tacatttaaa attatattaa 1980

cattttatt tcctttaatt tttatttttt gtgggctttt tattttacat tatttaactt 2040

gacatattac tctcttaatg 2060

<210> 2
<211> 1239
<212> DNA
<213> Candida albicans

<220>
<221> CDS
<222> (1)..(1236)

<400> 2

```
atg agt gaa agt gac gaa acc aaa tcg ata tca tct tta ata tct tct   48
Met Ser Glu Ser Asp Glu Thr Lys Ser Ile Ser Ser Leu Ile Ser Ser
  1               5                  10                  15

tct tct tca tca cgt ccc aaa aag tat att tgc aca tat gaa ggg tgt   96
Ser Ser Ser Ser Arg Pro Lys Lys Tyr Ile Cys Thr Tyr Glu Gly Cys
            20                  25                  30

gat aaa gcc tat aat cga cca tca tta tta gag caa cat tta aga acc  144
Asp Lys Ala Tyr Asn Arg Pro Ser Leu Leu Glu Gln His Leu Arg Thr
        35                  40                  45

cac agt aat gat cga ccg tat aaa tgt aca gtg gac gat tgt gat aaa  192
His Ser Asn Asp Arg Pro Tyr Lys Cys Thr Val Asp Asp Cys Asp Lys
    50                  55                  60

gca ttt ttc aga aaa tca cat ttg gaa aca cat att gta tca cat tcc  240
Ala Phe Phe Arg Lys Ser His Leu Glu Thr His Ile Val Ser His Ser
65                  70                  75                  80

gaa aaa aaa cca ttc cat tgt tca gtg tgt ggt aaa ggg gtt aat tct  288
Glu Lys Lys Pro Phe His Cys Ser Val Cys Gly Lys Gly Val Asn Ser
                85                  90                  95

cga caa cac ttg aaa aga cat gaa atc acc cat aca aag tca ttt aaa  336
Arg Gln His Leu Lys Arg His Glu Ile Thr His Thr Lys Ser Phe Lys
            100                 105                 110
```

```
tgt aca ttt gaa aat tgt caa gaa gca ttt tat aaa cat caa tct tta   384
Cys Thr Phe Glu Asn Cys Gln Glu Ala Phe Tyr Lys His Gln Ser Leu
        115                 120                 125

aga cat cat ata tta tct gtt cat gaa aaa aca tta acg tgt aaa caa   432
Arg His His Ile Leu Ser Val His Glu Lys Thr Leu Thr Cys Lys Gln
    130                 135                 140

tgt aat aaa gtt ttc act cga cct tca aaa tta gca caa cat aaa tta   480
Cys Asn Lys Val Phe Thr Arg Pro Ser Lys Leu Ala Gln His Lys Leu
145                 150                 155                 160

aaa cat cat ggt gga tct cct gct tat caa tgt gat cat cct ggt tgt   528
Lys His His Gly Gly Ser Pro Ala Tyr Gln Cys Asp His Pro Gly Cys
                165                 170                 175

ttt aaa aat ttc caa act tgg tca gta tta caa ttt cat ata aaa caa   576
Phe Lys Asn Phe Gln Thr Trp Ser Val Leu Gln Phe His Ile Lys Gln
            180                 185                 190

ctg cat cca aaa ctt aaa tgt cct aaa tgt ggt aaa ggt tgt gtt ggg   624
Ser His Pro Lys Leu Lys Cys Pro Lys Cys Gly Lys Gly Cys Val Gly
        195                 200                 205

aaa aaa ggt tta tct tca cat atg tta agt cat gat gat tct acc atg   672
Lys Lys Gly Leu Ser Ser His Met Leu Ser His Asp Asp Ser Thr Met
    210                 215                 220

atc aaa ata tgg act tgt gat tat tgt gat gtg ggg aaa ttt gca aag   720
Ile Lys Ile Trp Thr Cys Asp Tyr Cys Asp Val Gly Lys Phe Ala Lys
225                 230                 235                 240

aaa aat gaa tta gtt gaa cat tat aat atc ttc cat gat ggt aat atc   768
Lys Asn Glu Leu Val Glu His Tyr Asn Ile Phe His Asp Gly Asn Ile
                245                 250                 255

cct gat gat tta tta aag gaa act gaa gtg aaa aaa tta gag aac cta   816
Pro Asp Asp Leu Leu Lys Glu Thr Glu Val Lys Lys Leu Glu Asn Leu
            260                 265                 270

tta gat caa gga tcg aaa tta aat aat ttg cat gaa tta gaa aca gag   864
Leu Asp Gln Gly Ser Lys Leu Asn Asn Leu His Glu Leu Glu Thr Glu
        275                 280                 285

aaa tta aaa gtg gaa gaa gat gaa gaa gat gaa gaa gat agt cta gat   912
Lys Leu Lys Val Glu Glu Asp Glu Glu Asp Glu Glu Asp Ser Leu Asp
    290                 295                 300

gaa aaa aga agt gat gtt aga tca gac tca atg tca gct caa aga tca   960
Glu Lys Arg Ser Asp Val Arg Ser Asp Ser Met Ser Ala Gln Arg Ser
305                 310                 315                 320

ata aaa tca ttt act gct tct ttg gaa ggt tca aag agt gtt tct aaa   1008
Ile Lys Ser Phe Thr Ala Ser Leu Glu Gly Ser Lys Ser Val Ser Lys
                325                 330                 335

ctt att ctg aat agt ggg aag aag atc aat tgt cct aag aat aat tgt   1056
Leu Ile Ser Asn Ser Gly Lys Lys Ile Asn Cys Pro Lys Asn Asn Cys
            340                 345                 350

gat aga atg ttt tct aga gaa tat gat tta cgt cga cat ttg aaa tgg   1104
Asp Arg Met Phe Ser Arg Glu Tyr Asp Leu Arg Arg His Leu Lys Trp
        355                 360                 365
```

```
cat gat gat aat tta caa aga att gag tca ttc tta aat agt ata gaa   1152
His Asp Asp Asn Leu Gln Arg Ile Glu Ser Phe Leu Asn Ser Ile Glu
    370                 375                 380

aaa gaa gaa act cca gaa ggt gaa cca ttg gtt aaa aaa gcc agg atg   1200
Lys Glu Glu Thr Pro Glu Gly Glu Pro Leu Val Lys Lys Ala Arg Met
385                 390                 395                 400

gat tta ttg cca aat gaa aca tca gtg att tct cga taa               1239
Asp Leu Leu Pro Asn Glu Thr Ser Val Ile Ser Arg
                405                 410
```

<210> 3
<211> 412
<212> PRT
<213> Candida albicans

<400> 3

```
Met Ser Glu Ser Asp Glu Thr Lys Ser Ile Ser Ser Leu Ile Ser Ser
  1               5                  10                  15

Ser Ser Ser Ser Arg Pro Lys Lys Tyr Ile Cys Thr Tyr Glu Gly Cys
            20                  25                  30

Asp Lys Ala Tyr Asn Arg Pro Ser Leu Leu Glu Gln His Leu Arg Thr
        35                  40                  45

His Ser Asn Asp Arg Pro Tyr Lys Cys Thr Val Asp Asp Cys Asp Lys
    50                  55                  60

Ala Phe Phe Arg Lys Ser His Leu Glu Thr His Ile Val Ser His Ser
65                  70                  75                  80

Glu Lys Lys Pro Phe His Cys Ser Val Cys Gly Lys Gly Val Asn Ser
                85                  90                  95

Arg Gln His Leu Lys Arg His Glu Ile Thr His Thr Lys Ser Phe Lys
            100                 105                 110

Cys Thr Phe Glu Asn Cys Gln Glu Ala Phe Tyr Lys His Gln Ser Leu
        115                 120                 125

Arg His His Ile Leu Ser Val His Glu Lys Thr Leu Thr Cys Lys Gln
    130                 135                 140

Cys Asn Lys Val Phe Thr Arg Pro Ser Lys Leu Ala Gln His Lys Leu
145                 150                 155                 160

Lys His His Gly Gly Ser Pro Ala Tyr Gln Cys Asp His Pro Gly Cys
                165                 170                 175

Phe Lys Asn Phe Gln Thr Trp Ser Val Leu Gln Phe His Ile Lys Gln
            180                 185                 190

Ser His Pro Lys Leu Lys Cys Pro Lys Cys Gly Lys Gly Cys Val Gly
        195                 200                 205

Lys Lys Gly Leu Ser Ser His Met Leu Ser His Asp Asp Ser Thr Met
    210                 215                 220

Ile Lys Ile Trp Thr Cys Asp Tyr Cys Asp Val Gly Lys Phe Ala Lys
225                 230                 235                 240

Lys Asn Glu Leu Val Glu His Tyr Asn Ile Phe His Asp Gly Asn Ile
                245                 250                 255
```

Pro Asp Asp Leu Leu Lys Glu Thr Glu Val Lys Lys Leu Glu Asn Leu
260 265 270

Leu Asp Gln Gly Ser Lys Leu Asn Asn Leu His Glu Leu Glu Thr Glu
275 280 285

Lys Leu Lys Val Glu Glu Asp Glu Glu Asp Glu Glu Asp Ser Leu Asp
290 295 300

Glu Lys Arg Ser Asp Val Arg Ser Asp Ser Met Ser Ala Gln Arg Ser
305 310 315 320

Ile Lys Ser Phe Thr Ala Ser Leu Glu Gly Ser Lys Ser Val Ser Lys
325 330 335

Leu Ile Ser Asn Ser Gly Lys Lys Ile Asn Cys Pro Lys Asn Asn Cys
340 345 350

Asp Arg Met Phe Ser Arg Glu Tyr Asp Leu Arg Arg His Leu Lys Trp
355 360 365

His Asp Asp Asn Leu Gln Arg Ile Glu Ser Phe Leu Asn Ser Ile Glu
370 375 380

Lys Glu Glu Thr Pro Glu Gly Glu Pro Leu Val Lys Lys Ala Arg Met
385 390 395 400

Asp Leu Leu Pro Asn Glu Thr Ser Val Ile Ser Arg
405 410

<210> 4
<211> 21
<212> DNA
<213> Candida albicans

<400> 4
atgagtgaaa gtgacgaaac c 21

<210> 5
<211> 24
<212> DNA
<213> Candida albicans

<400> 5
attggaatgg ttttttttcg gaat 24

<210> 6
<211> 23
<212> DNA
<213> Candida albicans

<400> 6
tggtttcgtc actttcactc att 23

<210> 7
<211> 25
<212> DNA
<213> Candida albicans

<400> 7

atgttaagtc atgatgattc tacca 25

<210> 8
<211> 27
<212> DNA
<213> Candida albicans

<400> 8
ccttagaatt caccatgagt gaaagtg 27

<210> 9
<211> 27
<212> DNA
<213> Candida albicans

<400> 9
gctgagctcg agtattatcg agaaatc 27

United States Patent & Trademark Office

Office of Initial Patent Examination -- Scanning Division

SCANNED, #2

Application deficiencies found during scanning:

☑ Page(s) 4-5 of 5 of Declaration _____ were not present for scanning. (Document title)

☐ Page(s)_____ of_____ _____were not present for scanning. (Document title)

☐ ***Scanned copy is best available.***